Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CVTX - CV Therapeutics, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (144)	12/9/2003 6:52:08 PM
From: scaram(o)uche	Respond to of 411

"got focused on the key issues" (translation...... the expert panel has no issue with QTc prolongation.) That's it...... CVTX got what they wanted. The question is, did it do anything for the potential of bringing a MEDICINE to market, or did it further fuel resentment at FDA and/or merely feed Lange's ego? Looks like they're pressing hard for a restricted label, perhaps a phase IV? Again, I'm not that familiar with the company, so it's grain of salt stuff.